|Mr. Mark Diamond BSc, MBA, MAICD||Chief Exec. Officer, Managing Director and Director||N/A||N/A||N/A|
|Mr. Phillip Allen Hains BBus(Acc), MBA, CA||Chief Financial Officer and Company Sec.||N/A||N/A||58|
|Dr. George Tachas||Director of Drug Discovery & Patents||N/A||N/A||N/A|
|Susan Turner||Fin. & Admin. Mang.||N/A||N/A||N/A|
Antisense Therapeutics Limited engages in the research, development, and commercialization of novel antisense pharmaceuticals in Australia. The companys product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of insulin like growth factor 1 receptor to treat prostate cancer. Its product pipeline also includes ATL1103, a second generation antisense drug to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action. The company is based in Toorak, Australia.
Antisense Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.